ArticleFrontiers in endocrinology2025
Anti-Müllerian hormone, sex steroids, and metabolic profile in cord blood of pregnancies with type 2 diabetes and gestational diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: The prevalence of type 2 diabetes (T2D) and gestational diabetes (GD)among women of reproductive age has increased in recent decades, making it the most common pregnancy complication. Many studies have examined pregnancy complications in women with diabetes; however, the impact of diabetes on the intrauterine environment, specifically ovarian markers and metabolic profiles in very preterm infants at birth, has not been studied. This study aimed to investigate AMH, sex steroid levels, and the metabolic profile in venous cord blood (VCB) in gestations affected by type 2 diabetes (T2D) and gestational diabetes (GD). Material and methods: Hormonal profile was evaluated in VCB of pregnancies with T2D (n=24), GD (n=26), and pregnancies without diabetes (C, n=25). Only pregnancies carrying a female offspring were included. AMH, sex steroids, and metabolic function biomarkers, including glucose, insulin, IGF-1, and adiponectin (APN) were measured. Clinical and anthropometric data were assessed in the mothers and offspring. Results: AMH VCB levels were significantly higher in T2D than in GD and C pregnancies (P<0.01 and P<0.005, respectively). Dehydroepiandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) VCB levels were lower in T2D pregnancies than in GD and C (P < 0.01, P < 0.0001, respectively). APN levels were lower in T2D pregnancies than in C (P < 0.05). Additionally, higher insulin and IGF-1 VCB levels and HOMA-IR index were observed in T2D than in C and GD (P < 0.001, P<0.05, and P<0.05, respectively). No significant correlations were observed between maternal and AMH, insulin, IGF-1, and androgen VCB levels. Discussion: T2D disrupts the intrauterine environment, leading to increased insulin, IGF-1, HOMA-IR, and AMH concentrations and decreased adiponectin levels in VCB. These findings describe the impact that maternal T2D may have on the health and development of their offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.